Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
108 studies found for:    Peripheral Arterial Disease OR claudication OR peripheral vascular disease | Open Studies | NIH, U.S. Fed
Show Display Options
Rank Status Study
21 Recruiting Evaluation of the Tissue Genesis® Icellator Cell Isolation System™ to Treat Critical Limb Ischemia
Condition: Critical Limb Ischemia
Intervention: Device: TGI SVF material via intramuscular injection
22 Not yet recruiting Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
Conditions: Prediabetic State;   Atherosclerosis;   Metformin
Interventions: Drug: Metformin XR;   Drug: Placebo
23 Recruiting Role of a Novel Exercise Program to Prevent Post-thrombotic Syndrome
Condition: Acute Deep Vein Thrombosis
Interventions: Other: Exercise;   Other: Control
24 Recruiting Ugandan Non-Communicable Diseases and Aging Cohort
Conditions: HIV;   Cardiovascular Disease;   Chronic Obstructive Pulmonary Disease;   Atherosclerosis;   Hypertension;   Diabetes Mellitus
Intervention: Other: This is an observational study only
25 Recruiting Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia
Condition: Critical Limb Ischemia
Interventions: Procedure: Open surgical revascularization;   Device: Endovascular revascularization
26 Not yet recruiting Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial
Conditions: Deep Vein Thrombosis;   Post-Thrombotic Syndrome;   Venous Thrombosis
Interventions: Drug: Recombinant tissue plasminogen activator (rt-PA);   Drug: Standard Anticoagulation Therapy
27 Recruiting Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)
Condition: Systemic Lupus Erthematosus
Interventions: Radiation: PET/CT;   Drug: Pioglitazone;   Procedure: Vascular function studies
28 Recruiting Improving Blood Pressure and Cardiovascular Risk With Resistance Exercise in African Americans
Conditions: Hypertension;   Cardiovascular Diseases;   Vascular Diseases
Interventions: Other: Aerobic Training;   Other: Resistance Training
29 Recruiting 90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation;   Radiation: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8
30 Recruiting Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Conditions: Acute Biphenotypic Leukemia;   Acute Erythroid Leukemia in Remission;   Acute Leukemia in Remission;   Acute Megakaryoblastic Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Acute Myeloid Leukemia With FLT3/ITD Mutation;   Acute Myeloid Leukemia With Inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1;   Acute Myeloid Leukemia With Inv(3)(q21q26.2); RPN1-EVI1;   Acute Myeloid Leukemia With Multilineage Dysplasia;   Acute Myeloid Leukemia With t(6;9)(p23;q34); DEK-NUP214;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1);   B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Complete Remission;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Acute Myeloid Leukemia;   T Lymphoblastic Lymphoma
Interventions: Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
31 Recruiting Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Conditions: Adult Acute Lymphoblastic Leukemia;   Adult Acute Myeloid Leukemia;   Adult Diffuse Large B-Cell Lymphoma;   Adult Myelodysplastic Syndrome;   Adult Non-Hodgkin Lymphoma;   Aggressive Non-Hodgkin Lymphoma;   Childhood Acute Lymphoblastic Leukemia;   Childhood Acute Myeloid Leukemia;   Childhood Diffuse Large B -Cell Lymphoma;   Childhood Myelodysplastic Syndrome;   Childhood Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia in Remission;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Hematopoietic and Lymphoid Cell Neoplasm;   Mantle Cell Lymphoma;   Plasma Cell Myeloma;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   T-Cell Chronic Lymphocytic Leukemia;   T-Cell Prolymphocytic Leukemia;   Waldenstrom Macroglobulinemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Sirolimus;   Radiation: Total-Body Irradiation
32 Recruiting Peripheral Nerve Stimulation for Shoulder Pain: Dose Response
Conditions: Stroke;   Shoulder Pain
Intervention: Device: Peripheral Nerve Stimulation
33 Recruiting Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Conditions: B-Cell Prolymphocytic Leukemia;   Hypodiploidy;   Loss of Chromosome 17p;   Plasma Cell Leukemia;   Progression of Multiple Myeloma or Plasma Cell Leukemia;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Hodgkin Lymphoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Non-Hodgkin Lymphoma;   Refractory Plasma Cell Myeloma;   Refractory Small Lymphocytic Lymphoma;   t(14;16);   t(4;14);   T-Cell Prolymphocytic Leukemia;   Waldenstrom Macroglobulinemia
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
34 Recruiting Peripheral Nerve Stimulation and Motor Training in Stroke
Condition: Stroke
Intervention: Procedure: PNS
35 Recruiting Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: fludarabine phosphate;   Other: melphalan;   Radiation: total marrow irradiation;   Drug: tacrolimus;   Drug: sirolimus;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
36 Recruiting A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
Conditions: Multiple Myeloma;   Non-Hodgkin's Lymphoma
Interventions: Drug: Meloxicam;   Drug: Filgrastim
37 Recruiting Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
Conditions: Aggressive Non-Hodgkin Lymphoma;   Myelodysplastic/Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Aggressive Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Waldenstrom Macroglobulinemia
Interventions: Drug: Atorvastatin Calcium;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation
38 Not yet recruiting GEOHealth Hub: Household Air Pollution and Cardio-pulmonary and Immune Function Outcomes
Conditions: Household Air Polution;   Cardiovascular Diseases;   Lung Diseases;   Immune Dysfunction
Intervention: Device: Improved cook stove
39 Recruiting Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
Conditions: Hematologic Disease;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome;   Myeloproliferative Disorder
Intervention: Procedure: Stem cell transplantation
40 Recruiting Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
Conditions: Plasma Cell Leukemia;   Recurrent Plasma Cell Myeloma
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Drug: Tacrolimus

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.